HomepagePTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Vorige slotkoers
$ 19,94
Jaar-range
$ 16,38 - $ 23,73
Beurswaarde
71,03 bln. IDR
Gem. volume
1,13K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 7,91 bln. | 7,16% |
Bedrijfskosten | 2,29 bln. | 15,55% |
Netto inkomsten | 573,28 mld. | 6,97% |
Netto winstmarge | 7,25 | -0,14% |
Winst per aandeel | 12,41 | 7,73% |
EBITDA | 874,81 mld. | 1,14% |
Effectief belastingtarief | 23,01% | — |
Balans
Totale activa
Totale passiva
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 4,32 bln. | 45,45% |
Totale activa | 28,75 bln. | 5,78% |
Totale passiva | 4,84 bln. | 0,67% |
Totaal aandelenvermogen | 23,91 bln. | — |
Uitstaande aandelen | 46,15 mld. | — |
Koers-boekwaardeverhouding | 0,04 | — |
Rendement op activa | 6,15% | — |
Rendement op kapitaal | 7,16% | — |
Kasstroom
Nettomutatie in liquide middelen
(IDR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 573,28 mld. | 6,97% |
Operationele kasstroom | 1,16 bln. | 22,56% |
Kasstroom uit beleggingen | -176,64 mld. | 33,78% |
Kasstroom uit financiering | -421,11 mld. | 51,91% |
Nettomutatie in liquide middelen | 481,86 mld. | 1.978,42% |
Vrije kasstroom | 752,00 mld. | 13,84% |
Over
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Opgericht
10 sep 1966
Website
Werknemers
12.924